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I present evidence that the epidemic of Alzheimer’s disease is a new phenomenon exploding in the latter part of the 20th century
in developed countries. I postulate that a major causative factor in the epidemic is the coincident use of copper plumbing, and
the ingestion of inorganic copper leaching from the copper plumbing. I present evidence to support this hypothesis and discuss
various objections and criticisms that have been raised about the hypothesis, and my responses to these criticisms. I conclude that
the hypothesis is well supported by the evidence and deserves serious consideration, because if it is valid, it indentiﬁes a partially
preventable cause of Alzheimer’s disease.
1.Introduction
Alzheimer’s disease (AD), and mild cognitive impairment
(MCI) that precedes it, has become a huge medical problem.
The numbers are staggering. In the US there are currently
about 5 million cases of AD and a similar number of cases
of MCI [1]. We are in the US, so we are most familiar
with US numbers, but there is a similar high incidence in
Europe and most other developed countries of the world.
The economic costs are also staggering. These patients live
many years after the diagnosis and require increasing health
and caregiver care. Perhaps most important, the aﬀected
patients are robbed of a reasonable quality of life during
their elderly years. As the disease progresses, they gradually
become unaware of what is going on around them, fail to
recognize their loved ones, and lose the ability to function.
This loss of quality of life and dignity in such a large
proportion of our elderly should be unacceptable to us as a
society if it is at all preventable. We should leave no stone
unturned to ﬁnd preventable causes, if any exist, and to
develop new therapies.
We have come up with a hypothesis for a plausible,
potentiallypreventable,cause,namely,ingestionofinorganic
copper [2]. We do not claim this as a sole cause, but rather
it, along with a high fat diet, sets the stage for the disease to
develop, particularly if other risk factors are present.
What do we mean by inorganic copper? We diﬀerentiate
what we call organic copper, which is copper in food,
and which is bound up in organic protein molecules,
from simple salts of copper not bound to anything. The
latter, inorganic copper, is the kind of copper present in
drinking water and in copper supplements present in most
available vitamin/mineral supplement pills. Since there is
almostnoproteininuncontaminateddrinking water,copper
leached oﬀ copper plumbing pipes will combine with the
cations found in drinking water, such as sulfates, carbonates,
and phosphates, to form copper sulfate, copper carbonate,
and copper phosphate. Copper added to vitamin/mineral
supplement pills is also a simple salt, often copper sulfate.
As I will discuss, I believe inorganic copper, at least in part,
is handled diﬀerently by the body than organic copper, and
ends up in diﬀerent places.
At this point, I will brieﬂy review some aspects of the
metallochemistry of AD related to copper and zinc, so that
less specialized readers may have a better understanding of
the points being discussed. One of the hallmarks of AD
pathology in the brain is extracellular amyloid plaques [3].
These are polymers of beta amyloid, a polypeptide clipped2 International Journal of Alzheimer’s Disease
oﬀ the end of the amyloid precursor protein. The amyloid
plaquesarethoughttobetoxictoneuronsandarethoughtto
be an integral part of the pathogenesis of AD. These plaques
are very rich in copper and zinc, and for a time it was
thought both elements were involved in plaque formation
[4, 5]. However, it now seems likely that copper is required
for plaque formation while zinc is simply bound in large
amounts to the plaques. Indeed the plaques, representing a
sink for zinc, may add harmful depletion of zinc in the brain
[6]. It is already known, based on serum zinc levels, that AD
patients are zinc deﬁcient [7], and zinc plays important roles
in neuronal function. Thus, copper may be incriminated as
a toxic agent, while zinc may be protective, and the brain
zinc deﬁcient. Copper also contributes to generation of toxic
oxygen radicals in interaction with amyloid plaques [8].
These roles make extracellular copper a potential culprit in
the pathogenesis of AD.
Adding further fuel to the ﬁre of a role for copper in
AD pathogenesis is a series of papers from an Italian group
led by Dr. Rosanne Squitti. This group has focused on “free
copper” in the blood. Free copper is the copper in the blood
not covalently bound to ceruloplasmin, a copper containing
protein in the blood that accounts for 60–65% of blood
copper. The remaining copper is called free copper, although
it is not really free, but is loosely bound to molecules such as
serum albumin. Although not technically “free”, this copper
is freely available to contribute to cellular needs, and if the
free copper pool is expanded, to cause toxicity. This is most
markedly seen in untreated Wilson’s disease, an inherited
disease of copper accumulation and copper toxicity [9]. The
greatlyexpandedfreecopperpoolinthisdiseaseisassociated
with copper toxicity in brain and liver. Squitti and colleagues
have found that the free copper pool in the blood is also
increasedinADpatients[10],thattheincreaseinfreecopper
is correlated with a cognitive measure [11] and is predictive
of cognitive decline over the next year [12]. Although these
data do not prove copper causation, they are strong pieces of
evidence consistent with the copper causation theory.
In 2003, Sparks and Schreurs [13] did a landmark study
that strongly indicated that trace amounts of copper in
drinking water are toxic to the brain. They showed that
addition of 0.12ppm copper to the drinking water of a rabbit
model of AD greatly enhanced the amyloid plaque pathology
in the rabbit brain, but also caused a strong deterioration in
cognition. This work has been replicated in other AD models
[14],andbyotherworkers[15].Forreference,theEPAallows
1.3ppm copper in US drinking water for humans, over 10-
times the level enhancing AD in the animal models. For
further reference, if this amount of copper were increased in
f o o d ,i tw o u l dh a v eat r i v i a l ,n o n t o x i ce ﬀect. The human diet
ranges from about 0.8mg to 1.4mg/day of copper content.
0.12ppm additional copper would add 0.12mg/day, about
10% of the copper already there, and much less than the
50% plus variation in copper already present in the diets.
These data indicate that copper from drinking water is much
moretoxic to the brain than copper fromfood. Idiﬀerentiate
these two types of copper by referring to copper in drinking
water as inorganic copper, as opposed to the copper in
food, which is bound to food protein, which I call organic
copper. Since there are no signiﬁcant amounts of protein
in uncontaminated drinking water, by the above deﬁnition
copper in drinking water has to be inorganic.
Although not speciﬁcally focused on AD, there is another
study which speaks to the potential brain toxicity of inor-
ganic copper. Morris and colleagues [16] did a large study in
Chicago in which they evaluated intake of various nutrients
and looked at cognition change over a several-year period.
They found that subjects in the highest quintile of copper
intake, if they also ate a high fat diet, lost cognition at
six-times the rate of other groups. Subjects were in the
highest quintile of copper intake by virtue of daily ingestion
of vitamin-mineral supplement pills containing 1–3mg of
copper. This copper is inorganic by our deﬁnition, because
there is no protein in these supplement pills.
In a very nice review of whether there is too much or too
little copper in Alzheimer’s disease, Quinn et al. [17]r e v i e w s
the evidence for both sides. He keeps an open mind but
seems to favor two clinical trial approaches. One is copper
lowering, with agents like tetrathiomolybdate or zinc, using
ceruloplasminlevelsasaguidetocopperstatus.Thesecondis
a copper redistribution approach in which the drug, such as
one called PBT2, may redistribute copper from extracellular
to intracellular compartments. This approach envisions an
intracellular copper deﬁciency being present.
Returning to our inorganic copper causation hypothesis
for AD, as we have put this hypothesis forward in various
publications, presentations, and manuscript submissions, we
have run into a blizzard of objections, counter arguments,
and denial. These have come from publications, from
reviewers of our papers, from communications with workers
in the ﬁeld, and Alzheimer’s physicians. While we expect a
good deal of skepticism because our ideas about inorganic
copper as partially causative are quite diﬀerent from what
has been generally believed, we are a bit taken back by some
of the arguments against our hypothesis being deﬁnitely
and provably wrong, and others more or less obviously
wrong. In some cases there is obvious conﬂict of interest,
with objections coming from the copper industry and those
funded by the copper industry. In other cases there is
probablybiasagainstanewideabecausepeoplehavebecome
comfortable with their own existing ideas. In other cases
there may be discomfort with recognizing a major harmful
factor in our environment that perhaps should have been
recognized some time ago, if not long ago.
Thus, I have put this paper together to list the set of
subhypotheses that lead to our overarching hypothesis, and
to discuss the issues that have been raised surrounding each.
I acknowledge the fact that ingestion of inorganic copper as a
partiallycausativefactorinADisstillanincompletelyproven
hypothesis, but I point out there is compelling evidence
to support it. So, while my concepts are still an unproven
theory, I hope our skeptics will keep an open mind and
examine the evidence. Even if someone views our theories as
only having a slight chance of being correct, if they do prove
correct, it is extremely important for AD prevention. So let
us get on with the debate, and the further work needed to see
if we can eliminate a preventable cause of AD.International Journal of Alzheimer’s Disease 3
2. The Copper CausationHypothesis
Overarching Hypothesis. Ingestion of inorganic copper from
drinking water and from copper supplements is a risk factor
for AD and a major factor causing the AD epidemic.
Subhypotheses
(1) The epidemic of AD is a new disease phenomenon
and is associated with development.
(2) Ingestion of inorganic copper leached from copper
plumbing is a major factor in causing the AD
epidemic, with copper supplements possibly playing
a subsidiary role.
(3) Ingestion of inorganic copper contributes directly to
the free copper pool in the blood.
(4) Elevated free copper in the blood of AD patients is a
pathogenic factor in AD.
(1) Subhypothesis 1: The Epidemic of AD Is a New Disease
Phenomenon and Is Associated with Development
The relationship of this subhypothesis to copper is that in
subhypothesis 2 I am going to postulate that the epidemic of
AD is associated with the explosive use of copper plumbing
inthe20thcentury,andthatcopperleachingfromthecopper
pipes is partially causal of AD. Thus, I wish to establish that
the epidemic of AD represents something new, not present,
or hardly present, in the 19th century, for example, and is
associated with use of copper plumbing in the 20th century.
Supporting Data. Regarding the question of whether the
AD epidemic is a new disease phenomenon, the book by
WaldmanandLamb[18]isverywellresearchedonthistopic.
As far as I know, these are the ﬁrst authors to suggest the AD
epidemic is a new disease phenomenon, and if so, deserve
credit for this concept. They reviewed the extensive writings
of disease authorities who published in the latter part of the
19th century, and found, consistently, that AD did not exist,
or if it did, it must have been rare. There is the writing of
Osler, an internist, who compiled a seven-volume series of
books, with the help of colleagues, on all medical diseases.
Volume7,almost1000pageslong[19],wasondiseasesofthe
brainandnervoussystem.ThereisnomentionofanAD-like
disease. Similarly, Gowers, a neurologist, wrote extensively
on brain and neurologic diseases, and did not mention an
AD-like disease [20]. Similarly Freud (work collected by
Strachey et al.) who wrote extensively on psychiatric disease,
did not describe an AD-like disease [21]. Finally Boyd, who
wrote a comprehensive textbook on pathology, which was
put out several times as updated new editions, did not
describethehallmarksofADpathologyinthebrain,amyloid
plaques, and neuroﬁbrillary tangles [22].
Since AD is a disease of aging, Waldman and Lamb [18]
wondered whether lack of elderly people in the population
whenOsler,Gower,Freud,andBoydmadetheirobservations
was the cause of the absence of the disease in their
writings. To the contrary, they found that there was always
a substantial fraction of people over 60 in the relevant
populations. For example, in France, in 1911, more than half
of the population was still alive at age 60.
IhaveexaminedtheUScensusﬁguresfor1900andfound
that there were 3,184,363 people over age 60. At today’s pre-
valence, there should have been over 36,000 US cases, more
than enough for Boyd to ﬁnd positive AD brains at autopsy.
Regarding the question of whether the AD epidemic is
largely associated with development, Ferri et al. [23]g i v ea
summary of data for developed and undeveloped countries.
In general the data show a considerably higher frequency of
AD in developed countries.
C o n t r a r yD a t a ,C o n t r a r yV i e w ,a n dM yR e s p o n s e s :
Contrary View. A common view among AD workers is that
AD was always present, but the dementia was simply passed
over as part of normal aging, and no special attention was
paid to these patients.
My Response. This might account for the lack of attention
by the clinicians (Osler [19], Gowers [20], and Freud [21]),
although it is a little hard to believe given their quality
and attention to detail, but it does not explain why the
pathologist Boyd [22] did not see amyloid plaques and
neuroﬁbrillary tangles, pathological hallmarks of AD, in the
brains of patients autopsied.
Contrary View. Another common view is that the AD inci-
dence is increasing only because the disease is now better
recognized and labeled, and because of the increasing num-
ber of elderly people in the population.
MyResponse. Iagreethatbothofthesefactorsareinvolvedin
explaining the increasing prevalence. However, my position
is that there has to be something additional to explain the
absence of brains with AD pathology around the beginning
of the 20th century [22], and the very high current frequency
of such brains at autopsy. We pointed out in the previous
section that an elderly population was present in France and
the US 100 years ago, so simply more aged people in the
current population cannot explain the almost total absence
of the disease back then.
Contrary View. Anotherviewisthatthehighfat,highcalorie
diets of developed countries are a major causative factor
and a major reason for the explosive epidemic of AD in
the Western world. Indeed, Grant [24]h a ss h o w nas t r o n g
positive correlation between fat intake and AD prevalence
across numerous countries.
My Response. That a high fat diet is a major causative
factor for AD is a reasonable hypothesis. My hypotheses is
that a high fat diet interacts with copper to contribute to
causation. Thus, the Sparks and Schreurs [13]s t u d yi n v o l v e d
cholesterol feeding in the rabbit model where trace amounts
of copper greatly enhanced the disease, and the Morris et al.
[16] study found that those in the highest quintile of copper
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in cognition. There are biochemical reasons why the two
factors might interact in causation, for example, copper
oxidizes cholesterol and other fats into substance toxic to
the brain. However, a major role for copper whether in the
presence of a high fat diet or not, is supported by trace
copper enhancement of AD-like disease, in the mouse model
of AD, which does not receive a fat- or cholesterol-enriched
diet [14, 15]. Thus, my current view is that both factors are
causative,andinteracttogethertofurtherenhancecausation.
(2) Subhypothesis 2: Ingestion of Inorganic Copper
Leached from Copper Plumbing Is a Major Factor in Causing
the AD Epidemic with Copper Supplements Possibly
Playing a Subsidiary Role
Supporting Data. To give the reader insight as to possible
involvement of copper in AD causation, I would like to
brieﬂy review the interaction of copper with the molecules
intimately involved in AD pathogenesis. Beta amyloid, the
key molecule in amyloid plaques, binds copper and choles-
terol, causing oxidation of cholesterol to 7-OH cholesterol,
extremely toxic to neurons [25, 26]. Beta amyloid is cleaved
from amyloid precursor protein by beta secretase. Amyloid
precursor protein binds copper, and reduces it from copper
(II) to copper (I), which produces oxidative damage [27, 28].
Beta secretase also binds copper for activity. Both amyloid
plaques and neuroﬁbrillary tangles, hallmarks of AD brain
pathology, are major sites of generation of toxic oxygen
radicals [29]. Deferoxamine or EDTA, an iron or general
metal chelator, respectively, abolishes the generation of these
radicals, but replenishment with iron or copper restores
the activity [29]. Tau protein, a major building block for
neuroﬁbrillary tangles, binds copper, which is a causative
factor in tau aggregation [30].
In response to the six contrary views later in this
section, I will show how AD risk factors, apolipoprotein E4,
homocysteine, levels, and certain transferrin alleles, all tie in
with the copper causation hypothesis.
A major initiating stimulus for all of our thinking and
leading to the hypotheses proposed here was the 2003 study
of a cholesterol-fed rabbit model of AD by Sparks and
Schreurs [13]. By accident, but also by serendipity, they
discovered that trace amounts of copper (0.12ppm) added
to the otherwise distilled drinking water of these rabbits,
greatly enhanced the AD-like pathology in the brains, and
greatly decreased the rabbits’ ability to perform previously
learned tasks. In other words, trace amounts of copper in
the drinking water caused the two hallmarks of AD, amyloid
plaques and loss of cognition, to worsen. For reference, the
US Environmental Protection Agency (EPA) allows up to
1.3ppm copper in human drinking water, over 10-times as
much as worsened AD in the rabbit model. Similar and
even higher, levels of copper are permitted in drinking
water around the world. Sparks et al. [14]l a t e rc o n ﬁ r m e d
the AD enhancing eﬀects of trace amounts of copper in
noncholesterol-fed AD models, such as in the mouse model.
The eﬀect of these very low amounts of copper added to
drinking water enhancing AD pathology was conﬁrmed by
ag r o u pf r o mR o c h e s t e r[ 15].
Table 1: Copper levels in Nor American household drinking water.
Copper level
(ppm)
Number of households
Undetectable
0.01 80 (28%) 12 Considered safe
68
0.02
114 (41%)
36
Safety unknown
0.03 16
0.04 13
0.05 15
0.06 12
0.07 7
0.08 7
0.09 8
0.1
81(29%)
3
Cause
Alzheimer’s
disease in
animal models
0.2 34
0.3 14
0.4 9
0.5 6
0.6 2
0.7 3
0.8 2
0.9 2
1.0 2
1.1 2
0.2 1
1.3 1
1.4
5 (1.8%)
1
Above EPA limit
1.8 1
1.9 1
3.4 1
6.0 1
There is a rough correlation between the use of copper
plumbing tube around the world and the incidence of AD.
This is consistent with the hypothesis that copper leaching
from copper plumbing is causing AD.
Are there any data on whether signiﬁcant amounts of
copper are actually present in the drinking water of a
developed country, such as the U.S? Fortunately, there is. As
a result of evaluating copper levels in drinking water of my
Wilson’s disease patients, I accumulated data on 280 samples
of home drinking water from households all across North
America. The data are shown in Table 1. The data show that
2% of samples are over the EPA limit of 1.3ppm, 31% are
over 0.12ppm, the level that enhanced AD in the rabbit
and other animal models, 41% are between 0.12ppm and
0.01ppm, a level of unknown toxicity/safety, and only 28%International Journal of Alzheimer’s Disease 5
are less than 0.01ppm, a level we consider safe. Thus, 72%
of these North American drinking water samples either have
copper levels above that enhancing AD in animal models, or
are high enough to be of unknown safety in that regard.
The other common source of inorganic copper ingested
by humans is copper in vitamin/mineral supplements. In the
last 50 years or so it has become very common in the US, and
probably many other developed countries to ingest one or
more of these supplement pills per day. Almost all of these
pills have 1 to 3mg of copper. Since the dietary intake of
copper is about 1.0mg per day [31–34], this is a hefty dose of
copper, and it is all inorganic. Is there any evidence that this
highdoseofinorganiccopperhasaneﬀectoncognition?Yes,
in a large study of a general Chicago population published
in 2006, Morris and colleagues [16] found that those in the
highest quintile of copper intake, if they also ate a high fat
diet, lost cognition at six-times the rate of the rest of the
people. These people were in the highest quintile of copper
intakebecausetheytookmineralsupplementpillscontaining
copper.
Contrary Data, Contrary Views, and My Responses. Recently
I wrote a letter to the editor criticizing a collection of ﬁve
papers published in one issue of the Journal of Toxicology
and Environmental Health [35]. These papers concerned the
safety and toxicity of oral copper intake. In general, these
papers were nice reviews of various aspects of the topic.
My two main criticisms in my letter to the editor were that
noneoftheﬁvepapersdiﬀerentiatedthetoxicityofinorganic
copper in drinking water or in copper supplements from the
toxicity of copper bound to organic molecules in food, and
none of them referred to the literature emerging since 2003
on the toxicity of this inorganic copper. There was a lengthy
responseseniorauthoredbyDanzeisenetal.[36]t om ylett er
by 8 of the 14 authors of these ﬁve papers plus four other
scientists who were recruited to join in on the discussion.
In spite of the length of this response, it did not address
the two main criticisms listed above. But it did criticize
many aspects of the data cited in my letter that pointed to
the potential toxicity of inorganic copper ingestion. These
criticisms as they relate to the inorganic copper causation of
AD hypothesis will be discussed below.
Contrary View. One of the criticisms in the Danzeisen et al.
[36] paper was leveled at the Sparks and Schreurs [13]r a b b i t
model study. The authors mistakenly asserted that the study
only showed amyloid plaque reduction in the animals, and
that plaque reduction may not be related to “progression of
dementia.”
My Response. Danzeisen et al. [36] are mistaken. The Sparks
and Schreurs [13] paper showed not only plaque reduction
but loss of cognition in the copper treated animals.
Contrary View. The Danzeisen et al. [36] paper criticizes
Brewer et al.’s [35] conclusion from the Sparks and Schreurs
[13] study that copper exposure from drinking water in
itself can be a risk factor for AD. Danzeisen et al. [36]a r e
concerned about drawing conclusions from a rabbit model
of AD in which high cholesterol feeding preconditions the
animal to AD, so that worsening of the disease from addition
of copper to drinking water cannot be used to conclude that
copper alone in drinking water is a risk factor for AD. To
quote them, “This type of study in compromised animals
is applicable to neither the derivation of the maximum
contaminant level (MCL) for copper in drinking water,
nor its extrapolation to the nonobserved-adverse-eﬀect level
(NOAEL) for copper in humans.”
My Response. In my opinion drinking water should be
nontoxic and safe for all segments of the population.
When I served on the Committee to Evaluate Copper in
Drinking Water convened by the National Research Council
in 2000 [37], we considered, for example, whether the
currentallowablelevelofcopperwassafeforWilson’sdisease
heterozygouscarriers,whohaveminorextraaccumulationof
copper, and comprise only 1% of the population. Similarly,
if the segment of the population who eat a high cholesterol,
high fat diet, which is increasingly common in our society,
are especially vulnerable to get AD if they ingest low levels of
copper in drinking water, we must try to make the water safe
for them. And I point out that the mouse AD model, which
also showed vulnerability to 0.12ppm copper in drinking
water, does not depend on cholesterol feeding to produce the
disease [14].
I believe we have to be more comprehensive in assessing
the safe limits of copper in drinking water. The standard
methods consist of assessing acute eﬀects of copper levels
in drinking water in humans, but chronic eﬀects of copper
toxicity are evaluated using animal studies of copper in food.
The latter is inadequate, because the evidence seems pretty
clear from the AD animal model work that copper is much
mor et o xicinwat erthanitisinfood.I fittak esspecialanimal
model studies to reveal potential vulnerability of humans to
copper in drinking water for a speciﬁc disease, we should
pay attention to those studies, not ignore them by saying the
animals were “compromised” to produce the model.
Contrary View. Another one of the criticisms in the
Danzeisen et al. [36] paper was the Brewer et al. [35] citation
of the work of Morris et al. [16] referred to earlier. In this
work Morris et al. [16] found that those in the highest
quintileofcopperuptake,mostbeinginthisquintilebecause
of taking copper supplements, if they also ate a high fat diet,
suﬀered cognition loss at six-times the rate of other groups,
Danzeisen et al. [36] state, “It is not possible to separate the
factorsstudiedbytheseauthorsandimplicatecopperdirectly
in the presence of high fat intake.” Danzeisen et al. [36] also
worried about separating the eﬀect of copper intake from the
other ingredients of vitamin/mineral supplements.
My Response. Regarding the criticism of copper being toxic
only in the presence of a high fat intake, we point out that
these were normal people eating their normal diet. Surely
those eating this kind of diet which is an increasing number
of our people, also need protection from toxicity resulting
from ingestion of inorganic copper in supplement pills that
singles them out for cognition loss. The FDA, needs to6 International Journal of Alzheimer’s Disease
evaluate the potential toxicity of copper in supplements.
Regarding sorting out the eﬀects of copper versus other
ingredients in the supplements, Morris et al. [16] did that
in their statistical analysis. Copper, plus a high fat diet, were
the only culprits.
Contrary View. Danzeisen et al. [36] contradict the Brewer
et al. [35] statement that, “No formal toxicology studies of
copper in drinking water have ever been done,” by directly
saying this “is not correct.”
My Response. Danzeisen et al. [36] never speciﬁcally refute
the Brewer et al. [35] statement. Instead they cite various
typesofdatawhicharenotrelevanttothepoint,includingan
assessment,notbasedonachronictoxicitystudyofcopperin
drinking water, by the European Union, that up to 2.0mg/L
(2.0ppm) in water is safe, with the average intake currently
being 0.7ppm.
Contrary View. Danzeisen et al [36] cite studies by Kessler
et al. [38] in which AD patients were given 8 mg of copper as
copperorotate/dayforoneyear.Thecognitionofthepatients
did not get worse, leading to the conclusion that long-term
oral intake of copper is not a risk factor for AD.
My Response. These patients did not improve cognition
either! The hypothesis underlying the study was that AD
patients were copper deﬁcient, and copper therapy would be
eﬃcacious. Thus, the study was a negative one in terms of
its underlying hypothesis. However, because the patients did
not get worse, the authors turned their conclusion around,
and concluded copper administration was not harmful.
As to why the patients did not get worse given our
hypothesis about the role of copper toxicity, there are prob-
lems with this study leading to many possible explanations.
Copper orotate is relatively insoluble, and perhaps very
little was absorbed. No copper parameters were measured
in the patients, so there is no information on absorption.
It is possible that maximum eﬀects from exogenous copper
were already occurring, and that more exogenous copper
therefore had no additional eﬀect. Finally, AD is a slowly
progressive disease, and these were mild patients. Perhaps
the observation period was not long enough to aﬀect the
cognitive tests being carried out.
Contrary View. Danzeisen et al. [36]c r i t i c i z eB r e w e re ta l . ’ s
hypothesis that copper plumbing is a causal factor in AD.
They say genetic factors play a “particularly important role”
in AD, with age being the greatest nongenetic risk factor.
They say “we are not aware of any peer-reviewed scientiﬁc
evidence that supports Brewer et al.’s [35] conjecture that the
use of copper piping is a risk factor in AD.”
My Response. I agree that there are genetic risk factors
such as the apolipoprotein E4 alleles [39]a n dc e r t a i ng e n e s
involved in controlling iron, such as certain hemochromato-
sisalleles[40]andcertaintransferrinalleles[41].Inaddition,
elevated homocysteine levels are a risk factor [42]. Interest-
ingly, these all tie in with our hypothesis. The apo E4 protein
lacks a copper binding cysteine, so it cannot bind copper
while the apo E3 and E2 alleles have this cysteine. Thus apo
E4 is unable to remove copper from the brain. Homocysteine
interacts with copper to oxidize cholesterol, damaging to
neurons [43]. Iron build up increases oxidant stress, as does
copper build up, so the two work in the same manner. It
is our view that copper toxicity and a high fat diet [24]s e t
the stage for AD to develop, and other risk factors operate
on that stage to increase the likelihood of AD to develop.
Regarding the comment about no peer-reviewed evidence
(in other words no published paper) exists to support our
hypothesisaboutcopperplumbingasariskfactorforAD,the
explanation is that we claim priority as the ﬁrst to propose
this hypothesis. There has to be a ﬁrst worker to propose
a new hypothesis. If the hypothesis is correct, supporting
papers will come later.
Contrary View. Danzeisen et al. [36] cite a paper by Crouch
et al. [44] which presents evidence that there is an intracellu-
lar copper deﬁciency in the brain of an AD mouse model.
They interpret this to mean that ingestion of additional
inorganic copper would be a helpful rather than harmful.
They also cite papers which they say supports the idea of an
overall low level of copper in the human AD brain.
My Response. I do not agree that it is clear that the AD
brain has a low copper value. There is just as many papers
that ﬁnd copper levels elevated or normal in the AD brain
as ﬁnd it low. So this area is controversial. However, the
paper by Crouch et al. [44] is interesting. These authors
administer a copper binding agent to AD model mice. The
agent is designed to release its copper in the intracellular
environment. This agent improved AD-type pathology
and improved cognitive performance in a mouse model.
A sister compound which bound copper but did not
release it intracellularly had no eﬀect. Similar claims for the
drug clioquinol are not as clear, because it is not certain
that clioquinol releases bound copper intracellularly, and
clioquinol also binds and transports zinc.
The data in the Crouch et al. [44]p a p e rd os u g g e s t
that increasing the intracellular copper levels in the mouse
AD model is beneﬁcial. This possibly indicates that there
is intracellular copper deﬁciency. However, there appears to
be overlapping functions of copper and zinc in the synapse,
and recently it has become clear that AD patients are zinc
deﬁcient [7]. It is possible that the eﬀect of copper in the
Crouch et al. [44] study is substituting for a relative lack of
intracellular zinc.
However, even if an intracellular copper deﬁciency exists,
there is also evidence that extracellular copper enhances
oxidant damage in interaction with amyloid plaques and A
beta amyloid oligomers. If there is an intracellular copper
(and/or zinc) deﬁciency, and an extracellular copper toxicity,
then therapy can be aimed at both, restoring intracellular
copper (and/or zinc) levels, and reducing extracellular
copper levels. If intracellular copper deﬁciency exists, it
does not negate our hypothesis that excess ingestion of
inorganic copper contributes to AD development because of
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Contrary View. It has been suggested that the source water,
rather than copper plumbing, may contribute the toxic
copper to drinking water.
My Response. This may be true in parts of the world, and in
a few areas of the US. But in many areas of the US, source
water has low copper.
Contrary View. The epidemiologic data showing a low rate
of AD in Japan [45], a developed country, that shuns copper
plumbing, which we use to support the copper plumbing
causal hypothesis, has been criticized, because Japanese have
a diet diﬀerent than other countries. We have pointed
out that when Japanese migrate to Hawaii, where copper
plumbing is common, they develop a rate of AD typical of
developed countries [46], in further support of our hypoth-
esis. This concept has been criticized because the diet and
other environmental factors may also be diﬀerent in Hawaii.
My Response. We agree the epidemogic data, including the
Japanese epidemiologic data, do not prove our hypothesis.
The data, including the somewhat unusual Japanese data,
simply show consistency with the hypothesis.
Subhypothesis 3: Ingestion of Inorganic Copper Contributes
Directly to the Free Copper Pool in the Blood
Supporting Data. Normally food copper is metabolized by
the liver and channeled into safe pathways such as being
incorporated in to ceruloplasmin. The exceptional toxicity
of trace amounts of inorganic copper in drinking water in
AD animal model studies [13–15] suggests that at least some
of this copper must follow a diﬀerent route. We do have a
little direct data that this is indeed true. When we administer
inorganic copper orally labeled with 64C u ,w es e eaf r a c t i o n
of the label appear in the blood in 1-2 hours, too soon to
be processed by the liver [47]. The amount appearing is
5-6% of the administered label at both the 1- and 2-hour
time points, so a guesstimate of the area under the curve, a
rough estimate of absorption, is about 15%. We believe this
fraction of 64Cu-labeled inorganic copper is bypassing the
liver, is therefore not incorporated safely into ceruloplasmin,
contributes directly to the nonceruloplasmin free copper
pool, and represents what is happening to at least a portion
of the inorganic copper ingested in drinking water or copper
supplements. We hypothesize that this pathway for ingested
inorganic copper is a causal factor in AD.
Contrary View. One criticism of the above is that Ctr 1 is the
major copper transporter in intestinal cells [48], so it does
notseemlikelythatinorganiccoppercanbypasstheliverand
enter the free copper serum pool directly.
My Response. The animal model AD data [13–15] indicating
the toxicity of trace amounts of inorganic copper in drinking
water, and our 64Cu data [47], indicates something diﬀerent
is happening with at least a portion of ingested inorganic
copper. However, I agree that the mechanism by which some
of the inorganic copper is diﬀerently absorbed is unknown.
We can speculate that Ctr 1 may only recognize organically
bound copper, and some inorganic copper is absorbed
throughdiﬀerentchannels,suchascationchannels.Also,itis
possiblethatinorganiccopperisabsorbedquickly,asabolus,
and some simply bypasses the liver because of the high level.
At this point the mechanism is unknown.
Contrary View. Danzeisen et al. [36]c r i t i c i z eo u r64Cu data
by saying that we do not know how much inorganic copper
actually bypassed the liver and promptly appeared in the
blood because the speciﬁc activity of the radioactive copper
wasnotmeasured.Theyalsosay,sinceitwasgivenwithmilk,
some of it probably became protein bound.
My Response. Regarding the ﬁrst criticism, it represents a
misunderstanding of this kind of study. It is not necessary
to know the speciﬁc activity to know the proportion of
the label that was involved, which is what is of interest.
Regarding the second comment, some of the label probably
did bind to ovalbumin becoming “organic” copper. Thus, if
the 64Cu had been given in water and remained completely
inorganic, the 1- and 2-hour blood values might have been
considerably higher.
Subhypothesis 4: Elevated Free Copper in the Blood of AD
Patients Is a Pathogenic Factor in AD
Supporting Data. Elegant data on this point has been
published by Squitti and her colleagues [10–12, 49]. They
have shown the following.
(1) Free copper in the blood is elevated in AD patients
[10].
(2) Free copper negatively correlates with cognition in
AD patients [11].
(3) Free copper levels predict the rate of loss of cognition
in AD patients [12].
They also showed that free copper negatively correlates with
cognition in older normal women [49].
Number (1) above (elevated free copper in AD) has been
conﬁrmed [50, 51]. Our groups ﬁnds a higher percentage of
free copper in AD, and increased defective ceruloplasmin,
that is, ceruloplasmin that has lost its enzymatic activity
because it has lost some of its copper. We do not know
whether this process contributes to a higher free copper.
Arnal et al. [51] conﬁrm the higher free copper in AD and
alsoconﬁrmasigniﬁcantnegativecorrelationbetweenserum
free copper and cognition.
Contrary View. Danzeisen et al. [36] ﬁnd fault with the way
Squitti et al. [10–12, 49] determined free copper “values
arithmetically by measuring Cp-bound copper and subtract-
ing the value from total copper.” They say, “There is a scien-
tiﬁc consensus (voiced by seven experts in the ﬁeld in a peer-
reviewed article: Danzeisen et al. [52] that non-Cp copper
determined by arithmetic method is not sensitive to copper
status, and that its true value is very diﬃcult to measure”.
My Response. First, non-Cp copper determined arithmeti-
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for years in our Wilson’s disease work [9, 31, 53]. One
simply determines the Cp level by either an enzymatic
or immunologic method, calculates the amount of copper
b o u n dt oC pf r o mt h ek n o w na m o u n to fc o p p e rb o u n dt o
each mg of Cp, and subtracts that from total serum copper.
Of the two ways of measuring Cp, the enzymatic is probably
a little better, because in the immunologic method, a little
apo-Cp (without copper), is usually measured, the amount
determined by the antibody used. But either way, if the same
method is used consistently, it gives a very good estimate of
the non-Cp copper and its change over time.
If this methodology is so useless, why is it so elevated
in untreated Wilson’s disease patients experiencing acute
copper toxicity [9]? And why did it change so consistently
and predictably in our Wilson’s disease therapy studies [9],
And, coming back to the data being criticized, why does
it correlate so beautifully with cognition measures in AD
[11], why does it predict cognition loss in AD [12], and why
does it correlate with cognition in elderly women [49]? It is
not credible to believe all of this is coincidence or random
concurrence? Even the staunchest critics, even if they do not
believe non-Cp copper is in the pathologic pathway for AD,
have to admit it is at least a good marker of the AD process.
Contrary View. I have heard criticism that other authors
in the literature have reached opposite conclusions. I have
already discussed and criticized the work of the Bayer
group [38] who administered copper orotate to AD patients.
This same group published a paper that showed a lower
total serum copper and ceruloplasmin in AD patients with
cerebrospinal diagnostic markers, than AD patients without
thosemarkers,suggestingseverepatientsarecopperdeﬁcient
when compared to less severe patients [54].
My Response. This work is ﬂawed in that total serum copper
was measured not free copper, and total serum copper will
simply reﬂect Cp levels, since Cp contributes up to 90% of
serum copper.
Contrary View. Bayer et al. [55] have also published a
paper showing that dietary copper supplementation reduces
amyloid A beta production in an AD mouse model.
My Response. However, these mice are severely copper
deﬁcient, and copper supplementation helps them in many
ways because of this.
Contrary View. Klevay [56] has written a review entitled,
“Alzheimer’s disease as copper deﬁciency.” Klevay cites the
work of the Bayer group [38, 54, 55] already discussed here
in support of his hypothesis.
My Response. The title of this review is misguided in the
sense that it ignores the evidence for what the syndrome of
copper deﬁciency really is. For example, in recent years the
syndrome of copper deﬁciency has been amply illustrated by
excessive use of zinc containing-denture adhesive. The zinc
eventually causes severe copper deﬁciency. These patients
develop pancytopenia followed by myelopolyneuropathy,
which often leaves them severely neurologically crippled
[57, 58]. None of this occurs in AD, so it is not reasonable
to suggest that AD is a simple copper deﬁciency [56].
However, as we have previously discussed, we accept the
possibility that AD patients have a neuronal intracellular
copper deﬁciency. But this is very diﬀerent than what Klevay
[56] and the Bayer group [38, 54, 55] have been proposing.
Contrary View. An opinion has been expressed that the
biliary copper export pathway (the one that is defective in
Wilson’s disease) will protect against increases in serum free
copper.
My Response. My view is that this pathway is protective, but
not immediately sensitive to mild increases in free copper.
Thus, if the free copper levels are increased by increased
intake, the export pathway will respond and increase export,
but steady state levels of free copper are probably increased.
3. My Overviewof the Status of These Issues
It seems to me that subhypothesis 1 is not all that controver-
sial. Rather the doubters are just not informed. I urge them
to read Dying for a Hamburger by Waldman and Lamb [18].
This is an extremely well-researched book on the topic of the
AD epidemic being new, and that elderly people have always
existed in our population. Even if one thinks AD was passed
oﬀ as simply the normal dementia of aging, it is very diﬃcult
toexplaintheabsenceofamyloidplaquesandneuroﬁbrillary
tangles in the autopsy specimens of Boyd [22]. I am not
saying AD did not exist at all in the 1900s. It probably did.
Probably occasionally a constellation of risk factors would
come together and produce the disease. What I am saying
is it was relatively rare, and that there were enough elderly
people present for it to have easily shown up in the autopsy
specimens if it were occurring at today’s rate. Those who
wishtocounterthisargumentwouldhavetoeithershowthat
there were very few people over age 60, or that the plaques
and tangles were actually present in autopsy samples.
There is more controversy about subhypothesis 2, as is
evident from the length of the contrary view/My response
material regarding that subhypothesis.
One area where a legitimate diﬀerence of opinion can
exist is whether the Sparks and Schreurs [13] and other AD
animal work [14, 15], in which trace amounts (0.12ppm)
of copper in drinking water greatly enhances AD pathology
and cognition loss, can be extrapolated to the human. There
are four animal models studied, one of them does not
involve cholesterol feeding (the mouse), and they are all
consistent. Plus the mouse work has been conﬁrmed in
another laboratory [15] .S ot h ea n i m a lm o d e lw o r ki sv e r y
solid that trace amounts of copper in drinking water are
sharply more toxic than copper in food in AD-like causation.
But still, they cannot be extrapolated to the human with
absolute certainty. My position is that they should be taken
seriously as signaling a major potential (and preventable)
cause of human AD. Certainly not ignored, as did the ﬁve
papers in the Journal of Toxicology and Environmental
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A legitimate point is that besides the increase of copper
plumbingindevelopedcountries,manyotherenvironmental
changes have occurred, as well as behavioral changes in
people. Thus, assuming subhypothesis 1 is correct, any of
these factors could be responsible for the AD epidemic.
Waldman and Lamb [18], who wrote Dying for a Ham-
burger, in their otherwise well-researched book previously
r eferr edto ,postulatedthatitwasbeefeating,withADcaused
by prions in the beef. Beef eating certainly correlates with
development, but there is no evidence AD is a prion disease.
However, a factor associated with development is eating
more fat in the diet (including that in beef). Grant [24]
has shown there is a good correlation between a country’s
dietary fat consumption and the prevalence of AD. Since
much of the animal model data (plus the Morris et al. [16]
data) involves feeding cholesterol (or ingesting a high fat
diet), we believe copper and cholesterol/fat are synergistic
in AD causation. Copper can oxidize cholesterol and certain
fats into substances that are toxic in the brain. However,
one could postulate that a high fat diet, without copper
involvement, is the causative factor. This is a reasonable
hypothesis. But of course it ignores all the data involving
copper. Other unknown causatives factors associated with
development are also possible.
I do not believe the issue of whether adequate testing
has been done on the chronic toxicity of copper in drinking
water is very controversial. It just has not been done. None
of the statements or citations by Danzeisen et al. [36] show
that this type of work has ever been done. Besides animal
studies, epidemiologic studies on humans could be done,
relating disease incidence to levels of substances like copper
in drinking water. It is not an easy study, given that many
people move around and their source of drinking water
varies from time to time.
The possibility of a neuronal intracellular copper deﬁ-
ciency in AD, irrespective of potential toxicity from excess
extracellular copper, is a viable hypothesis and supported by
some emerging data [44]. This would make rational the use
of therapies which deliver copper intracellularly while not
adding extracellular copper. However, in the face of all the
evidence of extracellular copper toxicity in AD, intracellular
copper deﬁciency does not make rational the use of copper
supplementation to AD patients as done by the Bayer group
[38]. Nor does it justify a review, such as that of Klevay [56],
entitled, “Alzheimer’s disease as copper deﬁciency.”
I do not believe there is much controversy about whether
some of the ingested inorganic copper contributes directly to
the free copper pool, as proposed in subhypothesis 3. Even
Danzeisen et al. [36] referring to my interpretation of our
64Cu data as showing that some ingested inorganic copper
had bypassed the liver said, “this interpretation appears
correct.” Of course, the mechanism by which this occurs is
still unknown.
Regarding subhypothesis 4, the elegant work by Squitti
and colleagues [10–12] showing elevated serum free copper
in AD is not very controversial. It has been conﬁrmed by
others[50,51].Danzeisenetal.[36]criticizethemethod,but
this criticism seems groundless. What is still to be debated
and studied is what is the signiﬁcance of this elevation? Does
a higher serum free copper mean greater penetration of the
blood-brain barrier and an elevation of extracellular toxic
copper in the brain? Or alternatively, is it just a biomarker
of other, critical, pathogenic pathways? It is our hypothesis
that it is in the pathogenic sequence.
In conclusion, I believe our overarching hypothesis and
subhypotheses, of a key role of inorganic copper from
drinking water and supplements in causation of a new
epidemic, an epidemic of AD, is well supported. I do not
believe any of the contrary views, while some raise valid
points to consider, have dealt fatal blow to my hypotheses.
I emphasize that at this point my concepts of copper,
as one signiﬁcant causative factor among others, are not
ﬁnallyproven.Ibelievetheyareimportantbecauseiftheyare
correct, they point to a method of at least partial prevention
of AD, by lowering copper levels in drinking water and
stopping ingestion of copper supplements. Those that take
those steps now may beneﬁt while waiting for ﬁnal proof,
which may take a long time.
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